vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
DNA X, Inc. is the larger business by last-quarter revenue ($16.2M vs $10.7M, roughly 1.5× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -29.3%, a 52.8% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 7.9%). Over the past eight quarters, DNA X, Inc.'s revenue compounded faster (9.9% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ABUS vs SONM — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $16.2M |
| Net Profit | $2.5M | $-4.8M |
| Gross Margin | — | 11.2% |
| Operating Margin | 13.9% | -24.5% |
| Net Margin | 23.5% | -29.3% |
| Revenue YoY | 522.2% | 7.9% |
| Net Profit YoY | 112.7% | -89.2% |
| EPS (diluted) | $0.01 | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $16.2M | ||
| Q2 25 | $10.7M | $11.2M | ||
| Q1 25 | — | $16.7M | ||
| Q4 24 | — | $15.3M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | — | $9.1M | ||
| Q4 23 | $2.1M | $13.4M |
| Q3 25 | — | $-4.8M | ||
| Q2 25 | $2.5M | $-7.5M | ||
| Q1 25 | — | $458.0K | ||
| Q4 24 | — | $-21.6M | ||
| Q3 24 | — | $-2.5M | ||
| Q2 24 | — | $-6.6M | ||
| Q1 24 | — | $-2.9M | ||
| Q4 23 | — | $-1.4M |
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 28.2% | ||
| Q2 24 | — | 25.8% | ||
| Q1 24 | — | 31.8% | ||
| Q4 23 | — | 38.1% |
| Q3 25 | — | -24.5% | ||
| Q2 25 | 13.9% | -60.2% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | 55.3% | ||
| Q3 24 | — | -15.8% | ||
| Q2 24 | — | -56.2% | ||
| Q1 24 | — | -29.5% | ||
| Q4 23 | -967.2% | -9.3% |
| Q3 25 | — | -29.3% | ||
| Q2 25 | 23.5% | -66.8% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | — | -141.6% | ||
| Q3 24 | — | -16.7% | ||
| Q2 24 | — | -57.5% | ||
| Q1 24 | — | -31.9% | ||
| Q4 23 | — | -10.1% |
| Q3 25 | — | $-4.83 | ||
| Q2 25 | $0.01 | $-0.79 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | — | $-116.99 | ||
| Q3 24 | — | $-9.32 | ||
| Q2 24 | — | $-1.41 | ||
| Q1 24 | — | $-0.65 | ||
| Q4 23 | $-0.12 | $-0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $2.1M |
| Total DebtLower is stronger | $0 | $5.1M |
| Stockholders' EquityBook value | $83.0M | $-701.0K |
| Total Assets | $103.3M | $40.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $2.1M | ||
| Q2 25 | $37.4M | $2.0M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | — | $9.1M | ||
| Q2 24 | — | $9.6M | ||
| Q1 24 | — | $9.3M | ||
| Q4 23 | $126.0M | $9.4M |
| Q3 25 | — | $5.1M | ||
| Q2 25 | $0 | $2.9M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $0 | — |
| Q3 25 | — | $-701.0K | ||
| Q2 25 | $83.0M | $-1.3M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | — | $15.3M | ||
| Q2 24 | — | $17.5M | ||
| Q1 24 | — | $19.8M | ||
| Q4 23 | $106.0M | $22.4M |
| Q3 25 | — | $40.2M | ||
| Q2 25 | $103.3M | $36.1M | ||
| Q1 25 | — | $36.0M | ||
| Q4 24 | — | $39.7M | ||
| Q3 24 | — | $49.1M | ||
| Q2 24 | — | $45.9M | ||
| Q1 24 | — | $42.4M | ||
| Q4 23 | $144.4M | $56.0M |
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-7.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-7.0M | ||
| Q2 25 | $-15.7M | $-4.9M | ||
| Q1 25 | — | $-9.6M | ||
| Q4 24 | — | $-4.5M | ||
| Q3 24 | — | $-417.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-168.0K | ||
| Q4 23 | $-17.3M | $-351.0K |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-4.5M | ||
| Q3 24 | — | $-554.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-198.0K | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -29.6% | ||
| Q3 24 | — | -3.7% | ||
| Q2 24 | — | -29.8% | ||
| Q1 24 | — | -2.2% | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.3% | ||
| Q4 23 | 0.0% | — |
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | -20.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
